Decades of underfunding mean that we still lack the tests and treatments to tackle this brutal disease. Hope alone can’t fix this. People with pancreatic cancer need action now.
That’s why our research strategy is vitally important. It aims to transform the future for people with pancreatic cancer. From cutting-edge tests to cancer-killing therapies, our scientists are striving for earlier detection and better treatment.
We’re also investing in the brightest minds, to grow the research community and accelerate the life-saving breakthroughs that we so urgently need.
Late diagnosis is one of the biggest issues in pancreatic cancer but we’re investing in ground-breaking research to change this.
As well as investing in research to save lives, we’re also working to transform people’s experience of pancreatic cancer, funding new approaches and encouraging innovative thinking.
Our strategy lays out how we will work with world leading researchers and with people affected by pancreatic cancer, to fund research that will transform and save lives.
Researchers will find the breakthroughs needed in pancreatic cancer, so we must do everything we can to build and support the community.
Find out more about opportunities for funding and support for the pancreatic cancer research community. Together we are the research community taking pancreatic cancer on.
4 June 2026
Only 12% of people with pancreatic cancer are given the chance to take part in a clinical trial, emphasising the lack of progress in developing treatm...
3 June 2026
Today marks the launch of our Demand Survival Now petition, calling on governments across the UK to fund more research for treatment breakthroughs
31 May 2026
Our comment on daraxonrasib results and the promising group of therapies known as KRAS inhibitors.
4 June 2026
Only 12% of people with pancreatic cancer are given the chance to take part in a clinical trial, emphasising the lack of progress in developing treatm...
3 June 2026
Today marks the launch of our Demand Survival Now petition, calling on governments across the UK to fund more research for treatment breakthroughs
31 May 2026
Our comment on daraxonrasib results and the promising group of therapies known as KRAS inhibitors.
